Skip to main content
Home > Week in Review > Clinical Results

Chronological Index of : Clinical Results

 Current Issue
  • Vepoloxamer: Phase III data

    Mast Therapeutics Inc. (NYSE-M:MSTX), San Diego, Calif. Product: Vepoloxamer (MST-188) (formerly ANX-188) Business: Hematology Molecular target: NA Description: Antithrombotic poloxamer that binds to hydrophobic …

    Published on 9/26/2016
  • Zebinix: Phase III data

    Bial-Portela & Ca. S.A., S. Mamede do Coronado, Portugal Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506), Osaka, Japan Product: Zebinix (Aptiom) eslicarbazepine acetate (BIA 2-093, SEP-0002093) (formerly Stedesa) …

    Published on 9/26/2016
  • Alpha galactosidase: Additional Phase I/II data

    Protalix BioTherapeutics Inc. (NYSE-M:PLX; Tel Aviv:PLX), Carmiel, Israel Product: Alpha galactosidase (PRX-102) Business: Endocrine/Metabolic Molecular target: Alpha galactosidase A Description: Plant cell-expressed …

    Published on 9/19/2016
  • Imetelstat: Interim Phase II data

    Geron Corp. (NASDAQ:GERN), Menlo Park, Calif. Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Product: Imetelstat (JNJ-63935937, GRN163L) Business: Hematology Molecular target: Telomerase Description: Oligonucleotide …

    Published on 9/19/2016
  • Imetelstat: Interim Phase II/III data

    Geron Corp. (NASDAQ:GERN), Menlo Park, Calif. Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Product: Imetelstat (JNJ-63935937, GRN163L) Business: Cancer Molecular target: Telomerase Description: Oligonucleotide that…

    Published on 9/19/2016
  • Indacaterol/glycopyrronium bromide: Additional Phase III data

    Sosei Group Corp. (Tokyo:4565), Tokyo, Japan Vectura Group plc (LSE:VEC), Chippenham, U.K. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Product: Indacaterol/glycopyrronium bromide (Ulunar Breezhaler, Ultibro …

    Published on 9/19/2016
  • LJPC-401: Phase I data

    La Jolla Pharmaceutical Co. (NASDAQ:LJPC), San Diego, Calif. Institut National de la Sante et de la Recherche Medicale (INSERM), Paris, France Product: LJPC-401 Business: Hematology Molecular target: NA Description: …

    Published on 9/19/2016
  • Meloxicam: Phase II data

    Recro Pharma Inc. (NASDAQ:REPH), Malvern, Pa. Product: Meloxicam (N1539) Business: Neurology Molecular target: Cyclooxygenase-2 (COX-2) Description: Cyclooxygenase-2 (COX-2) inhibitor developed using NanoCrystal …

    Published on 9/19/2016
  • Mongersen: Interim Phase Ib data

    Celgene Corp. (NASDAQ:CELG), Summit, N.J. Nogra Pharma Ltd., Dublin, Ireland Product: Mongersen (GED-0301) Business: Autoimmune Molecular target: SMAD family member 7 (SMAD7) (MADH7) Description: Antisense …

    Published on 9/19/2016
  • Motrem: Phase I data

    Inotrem S.A., Nancy, France Product: Motrem Business: Infectious Molecular target: Triggering receptor expressed on myeloid cells 1 (TREM1) Description: Triggering receptor expressed on myeloid cells 1 (TREM1) pathway …

    Published on 9/19/2016
  • Naldemedine: Phase III data

    Shionogi & Co. Ltd. (Tokyo:4507), Osaka, Japan Product: Naldemedine (S-297995) Business: Gastrointestinal Molecular target: Mu opioid receptor (MOR) (OPRM1) Description: Oral peripheral mu opioid receptor (MOR; OPRM1) …

    Published on 9/19/2016
  • Omega-3 phospholipids: Bridging study data

    Acasti Pharma Inc. (TSX-V:APO; NASDAQ:ACST), Laval, Quebec Product: Omega-3 phospholipids (CaPre) Business: Endocrine/Metabolic Molecular target: NA Description: Long-chain omega-3 phospholipids sourced from krill oil …

    Published on 9/19/2016
  • Optune: Additional Phase III data

    Novocure Ltd. (NASDAQ:NVCR), Isle of Jersey Product: Optune (NovoTTF-100A) Business: Cancer Molecular target: NA Description: Non-invasive portable device that disrupts the division of cancer cells in the brain using …

    Published on 9/19/2016
  • Oral tecovirimat: Phase III data

    Siga Technologies Inc. (NASDAQ:SIGA), New York, N.Y. Product: Oral tecovirimat (oral TPOXX) (oral ST-246) Business: Infectious Molecular target: Not available Description: Oral small molecule antiviral Indication: Treat…

    Published on 9/19/2016
  • PA101: Phase II data

    Patara Pharma Inc., San Diego, Calif. Product: PA101 (formerly PA101B) Business: Pulmonary Molecular target: G protein-coupled receptor 35 (GPR35) Description: G protein-coupled receptor 35 (GPR35) agonist immune …

    Published on 9/19/2016
  • PrEP-001: Phase IIa data

    hVIVO plc (LSE:HVO), London, U.K. PrEP Biopharm Ltd., London, U.K. Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Product: PrEP-001 (formerly JNJ-43260295) Business: Infectious Molecular target: Undisclosed …

    Published on 9/19/2016
  • Roclatan netarsudil/latanoprost: Phase III data

    Aerie Pharmaceuticals Inc. (NASDAQ:AERI), Bedminster, N.J. Product: Roclatan netarsudil/latanoprost (PG324) Business: Ophthalmic Molecular target: Rho kinase; Norepinephrine transporter Description: Fixed-dose …

    Published on 9/19/2016
  • RPL554: Phase IIa data

    Vernalis plc (LSE:VER), Winnersh, U.K. Verona Pharma plc (LSE:VRP; Xetra:I9S), London, U.K. Product: RPL554 Business: Pulmonary Molecular target: Phosphodiesterase-3 (PDE-3); Phosphodiesterase-4 (PDE-4) Description: …

    Published on 9/19/2016
  • SNS-062: Preliminary Phase Ia data

    Biogen Inc. (NASDAQ:BIIB), Cambridge, Mass. Sunesis Pharmaceuticals Inc. (NASDAQ:SNSS), South San Francisco, Calif. Product: SNS-062 Business: Cancer Molecular target: Brutons tyrosine kinase (Btk) Description: Oral non…

    Published on 9/19/2016
  • Sotagliflozin: Phase III data

    Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX), The Woodlands, Texas Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Product: Sotagliflozin (SAR439954) (formerly LX4211 tablet) Business: Endocrine/Metabolic Molecular target:…

    Published on 9/19/2016
  • Spiriva Respimat tiotropium bromide: Phase III data

    Boehringer Ingelheim GmbH, Ingelheim, Germany Product: Spiriva Respimat tiotropium bromide Business: Inflammation Molecular target: Muscarinic acetylcholine receptor M3 (CHRM3) (HM3) Description: Once-daily inhaled …

    Published on 9/19/2016
  • Spiriva Respimat tiotropium bromide: Phase III data

    Boehringer Ingelheim GmbH, Ingelheim, Germany Product: Spiriva Respimat tiotropium bromide Business: Inflammation Molecular target: Muscarinic acetylcholine receptor M3 (CHRM3) (HM3) Description: Once-daily inhaled …

    Published on 9/19/2016
  • Spiriva Respimat tiotropium bromide: Phase III data

    Boehringer Ingelheim GmbH, Ingelheim, Germany Product: Spiriva Respimat tiotropium bromide Business: Inflammation Molecular target: Muscarinic acetylcholine receptor M3 (CHRM3) (HM3) Description: Once-daily inhaled …

    Published on 9/19/2016
  • Spiriva Respimat tiotropium bromide: Phase III data

    Boehringer Ingelheim GmbH, Ingelheim, Germany Product: Spiriva Respimat tiotropium bromide Business: Inflammation Molecular target: Muscarinic acetylcholine receptor M3 (CHRM3) (HM3) Description: Once-daily inhaled …

    Published on 9/19/2016
  • Spiriva Respimat tiotropium bromide: Phase II/III data

    Boehringer Ingelheim GmbH, Ingelheim, Germany Product: Spiriva Respimat tiotropium bromide Business: Inflammation Molecular target: Muscarinic acetylcholine receptor M3 (CHRM3) (HM3) Description: Once-daily inhaled …

    Published on 9/19/2016

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993